InvestorsHub Logo
Followers 6
Posts 863
Boards Moderated 0
Alias Born 09/28/2012

Re: Fred Kadiddlehopper post# 7288

Thursday, 12/08/2022 9:21:52 PM

Thursday, December 08, 2022 9:21:52 PM

Post# of 8591
And yet: Benchmark Adjusts Price Target on Halozyme Therapeutics to $68 From $55, Maintains Buy Rating.

Pretty strong stock action in spite of the recent substantial insider sale (Matthew Posard 30K shares).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News